Elan and Biogen Idec can breathe a little easier having announced the second round of positive results about the safety of their multiple sclerosis drug Tysabri. These results, which come less than a year after the voluntary withdrawal of the drug from the US market following the death of two patients from a fatal brain disorder, suggest a promising future could still be possible for Tysabri.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions